WILMINGTON, Del., May 05, 2022--Incyte Announces European Commission Approval of Jakavi (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic GVHD.
WILMINGTON, Del., May 04, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.
View more earnings on INCYSee more from BenzingaThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme LayoffsGlobal Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600MDon't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.